Hepatitis C virus antibodies among risk groups in Turkey

Abstract

In order to determine the prevalence of hepatitis C virus (HCV) infection in the Black Sea region in Turkey, 287 serum samples taken from risk groups were investigated for anti-HCV antibodies using HCV EIA system. Anti-HCV antibodies were found to be positive in 51.2% of chronic haemodialysis patients, 20.6% of probable acute non-A, non-B hepatitis patients, 4% of patients who had multiple blood transfusions, 1.5% of the health personnel, while in new haemodialysis patients anti-HCV antibodies were not found.

Prevalence of Antibodies to Hepatitis C Virus among Hemodialysis Patients in Damascus, Syria

“…The prevalence of anti-HCV in HD patients in our study (48.9%) is comparable to that reported for other countries in the Middle East and other parts of the world [15][16][17][18][19]. However, it is higher than that reported in western countries [9][10][11][12] and the USA [13] and lower than that reported for Egypt [8] and Saudi Arabia [14].…”

Soroprevalência do vírus da hepatite C na população em diálise de Goiânia, GO

“…Na Alemanha, foi observada uma prevalência de 7,4% 7 , na Itália, 18,4% 6 , Califórnia (EUA), 15,7% 16 , Austrália, 10% 12 . Países do Oriente apresentam uma soropositividade mais elevada, na Turquia, 51,2% 8 , Oman, 26,5% 1 , no Japão 20,4% 5 . Para os pacientes, a exposição a produtos sanguíneos contaminados é um fator epidemiológico importante, porém a utilização d e t é c n i c a s d e d i á l i s e e m u n i d a d e s hospitalares e/ou ambulatoriais fechadas tem sido considerado como fator de risco.…”

Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C

“…The prevalence of HCV infection in developing countries is generally much higher than that observed among dialysis patients in industrialized countries, ranging from 8.5 to 75% in published studies 1–3 . In Turkey, the prevalence of HCV is 31.4–51% in hemodialysis patients 4–6 …”